Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Economic evaluation of PET and PET/CT in oncology: Evidence and methodologic approaches.
J. Nucl. Med. 51, 401-412 (2010)
PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for staging of non-small cell lung cancer and differential diagnosis of solitary pulmonary nodules because PET and PET/CT have been found to be cost-effective for those uses. Additional indications that are covered by health care systems in the United States and several European countries include staging of gastrointestinal tract cancers, breast cancer, malignant lymphoma, melanoma, and head and neck cancers. Regarding these indications, diagnostic effectiveness and superiority over conventional imaging modalities have been shown, whereas cost-effectiveness has been demonstrated only in part. This article reports on the current knowledge of economic evaluations of PET and PET/CT in oncologic applications. Because more economic evaluations are needed for several clinical indications, we also report on the methodologies for conducting economic evaluations of diagnostic tests and suggest an approach toward the implementation of these tests in future clinical studies.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Positron emission tomography; Computerized tomography; Cost-effectiveness; Image fusion; Tumor staging; Response to therapy; Treatment individualization
ISSN (print) / ISBN
0161-5505
e-ISSN
1535-5667
Journal
Journal of Nuclear Medicine
Quellenangaben
Volume: 51,
Issue: 3,
Pages: 401-412
Publisher
Society of Nuclear Medicine and Molecular Imaging
Non-patent literature
Publications
Reviewing status
Peer reviewed